Compounds > ulifloxacin
Page last updated: 2024-12-07

ulifloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ulifloxacin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124225
CHEMBL ID345937
CHEBI ID35044
SCHEMBL ID1149364
MeSH IDM0487712

Synonyms (41)

Synonym
AC-2033
6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
112984-60-8
nm 394
ulifloxacin
CHEMBL345937
chebi:35044 ,
6-fluoro-1-methyl-4-oxo-7-piperazin-1-yl-1h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
A802713
6-fluoro-1-methyl-4-oxo-7-piperazin-1-yl-1h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid;6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-
nm-394
6-fluoro-1-methyl-7-(1-piperazinyl)-4-oxo-4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid
6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
c16h16fn3o3s
FT-0642762
c38638h76y ,
unii-c38638h76y
(1rs)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid
ulifloxacin [inn]
6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid
AKOS015901597
ulifloxacin [who-dd]
6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-1h,4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
NCGC00253642-01
cas-112984-60-8
tox21_113769
dtxcid1031410
dtxsid0057621 ,
SCHEMBL1149364
SUXQDLLXIBLQHW-UHFFFAOYSA-N
6-fluoro-l-methyl-4-oxo-7-piperazin-l-yl-4h-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid
Q-101932
af 3013; nad 394; nm 394
mfcd00882994
rkl10077
Q27116386
AS-13602
BCP13622
6-fluoro-1-methyl-4-oxo-7-piperazin
6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-[1,3]thiazeto[3,2-a]quinoline-3-carboxylicacid

Research Excerpts

Overview

Ulifloxacin (PUFX) is a prodrug-type new quinolone antibiotic. It is effective against pneumonia.

ExcerptReferenceRelevance
"Ulifloxacin is a new quinolone antibiotic and it is effective against pneumonia. "( Active uptake of ulifloxacin from plasma to lung that controls its concentration in epithelial lining fluid.
Aoki, M; Hayashi, H; Hayashi, M; Iguchi, M; Kurosawa, T; Shibasaki, S, 2009)		2.14
"Prulifloxacin (PUFX) is a prodrug-type new quinolone antibiotic and immediately converted to an active metabolite, ulifloxacin (UFX). "( Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin, in rats.
Aoki, M; Iguchi, M; Kato, Y; Kurosawa, T; Shibasaki, S; Tsuji, A; Yagi, Y, 2007)		1.33

Actions

ExcerptReferenceRelevance
"Prulifloxacin did not increase revertant colonies significantly in any of the test strains with or without metabolic activation system (S9 mix)."( [Mutagenicity studies of prulifloxacin (NM441) and the active metabolite (NM394)].
Ando, M; Iwakura, K; Kojima, M; Shindo, Y; Sumi, N; Tamura, H; Watanabe, M; Yamashita, Y, 1996)		1.15

Toxicity

ExcerptReferenceRelevance
" These findings help in management of prulifloxacin induced adverse effects by appropriate dose selection in clinical practice."( Correlation among the toxicity profiling (28-days repeated oral dose toxicity), toxicokinetics and tissue distribution data of ulifloxacin, the active metabolite of prulifloxacin in Wistar albino rats.
Das, AK; Nandi, U; Pal, TK; Roy, B, 2012)		0.85

Bioavailability

ExcerptReferenceRelevance
" To increase the bioavailability of NM394, various prodrugs were synthesized and tested."( In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative.
Kise, M; Kitano, M; Matsuda, M; Nishino, T; Ozaki, M; Segawa, J; Tomii, Y, )		0.13

Dosage Studied

Prulifloxacin is a safe quinolone and is well tolerated in both subjects with normal renal function and patients with impaired renal function. It requires a minimal dosage adjustment only in patients with severe renal impairment. The amount of ulifl Oxacin excreted in urine over a 24-h dosing period was similar in subjects withnormal renal function, but lower in those with moderate and severe renal impairments.

ExcerptRelevanceReference
" No effects caused by the repeated dosing were seen in the plasma concentrations."( [A 4-week intravenous toxicity study of the active metabolite (NM394) of prulifloxacin (NM441) in rats followed by a 4-week recovery test].
Iketani, M; Ishida, S; Iwakura, K; Shindo, Y; Sumi, N; Tamura, K; Yamazaki, S, 1996)		0.52
" No effects caused by the repeated dosing were seen in the plasma concentrations."( [A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test].
Fukuda, K; Iwakura, K; Nishimura, N; Shindo, Y; Sumi, N; Tamura, K; Yamazaki, S, 1996)		0.57
" No effects caused by the repeated dosing were seen in the plasma concentrations."( [A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test].
Ide, M; Iwakura, K; Nagatani, M; Oda, S; Shindo, Y; Sumi, N; Tamura, K, 1996)		0.57
" The amount of ulifloxacin excreted in urine over a 24-h dosing period was similar in subjects with normal renal function and patients with mild impaired renal function, but lower in those with moderate and severe renal impairment."( New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.
Ammendola, M; Comandini, A; Coppola, P; Del Vecchio, A; Di Loreto, G; Garofolo, F; Picollo, R; Tellone, V; Tongiani, S, 2018)		1.1
"Our data show that prulifloxacin is a safe quinolone and is well tolerated in both subjects with normal renal function and patients with impaired renal function, requiring a minimal dosage adjustment only in patients with severe renal impairment."( New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.
Ammendola, M; Comandini, A; Coppola, P; Del Vecchio, A; Di Loreto, G; Garofolo, F; Picollo, R; Tellone, V; Tongiani, S, 2018)		1.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency17.79660.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency0.94390.000714.592883.7951AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency4.64680.001022.650876.6163AID1224838; AID1224893
activating transcription factor 6Homo sapiens (human)Potency0.95210.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (225)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID546628Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546652Antibacterial activity against Shigella sp. assessed as growth inhibition at 0.12 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546629Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID70781In vitro antibacterial activity against Escherichia coli NIH JC-21992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID546975Antibacterial activity against Aeromonas veronii by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID203190In vitro antibacterial activity against Shigella flexneri 2a EW-101992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID546927Antibacterial activity against Salmonella enterica serovar Enteritidis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546936Antibacterial activity against Salmonella enterica serovar Choleraesuis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546646Antibacterial activity against Shigella sp. assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546642Antibacterial activity against Salmonella sp. assessed as growth inhibition at 0.016 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546921Antibacterial activity against Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546970Antibacterial activity against Aeromonas caviae assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546925Antibacterial activity against Salmonella enterica serovar Typhimurium assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546669Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 1 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546674Antibacterial activity against Plesiomonas shigelloides assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547209Antibacterial activity against blood-borne Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547173Antibacterial activity against Vibrio cholerae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546938Antibacterial activity against Salmonella enterica serovar Choleraesuis assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546630Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.016 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546643Antibacterial activity against Salmonella sp. assessed as growth inhibition at 0.03 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID123085In vitro antibacterial activity against Micrococcus luteus ATCC 93411992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID546963Antibacterial activity against Yersinia pseudotuberculosis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546945Antibacterial activity against Salmonella enterica serovar Heidelberg by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547175Antibacterial activity against Vibrio cholerae assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546935Antibacterial activity against Salmonella enterica serovar Paratyphi assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546937Antibacterial activity against Salmonella enterica serovar Choleraesuis assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547201Antibacterial activity against enteropathogenic Escherichia coli assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546966Antibacterial activity against Aeromonas hydrophila by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546922Antibacterial activity against Escherichia coli assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546952Antibacterial activity against Shigella flexneri assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546661Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546673Antibacterial activity against Plesiomonas shigelloides assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546958Antibacterial activity against Shigella dysenteriae assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547182Antibacterial activity against Vibrio fluvialis by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546640Antibacterial activity against Salmonella sp. assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547176Antibacterial activity against Vibrio parahaemolyticus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546933Antibacterial activity against Salmonella enterica serovar Paratyphi by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID608511Antibacterial activity against Escherichia coli KD652011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
AID546634Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.25 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546954Antibacterial activity against Shigella boydii by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546942Antibacterial activity against Salmonella enterica serovar Virchow by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546656Antibacterial activity against Yersinia sp. assessed as growth inhibition at 0.016 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID203317In vitro antibacterial activity against Serratia marcescens IFO 37361992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID547203Antibacterial activity against enteroaggregative Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546928Antibacterial activity against Salmonella enterica serovar Enteritidis assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547186Antibacterial activity against Vibrio vulnificus assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547180Antibacterial activity against Vibrio alginolyticus assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547192Antibacterial activity against Campylobacter jejuni assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546676Antibacterial activity against Vibrio sp. assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546941Antibacterial activity against Salmonella enterica serovar Newport assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546670Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 2 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546971Antibacterial activity against Aeromonas caviae assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID207390In vitro antibacterial activity against Staphylococcus aureus 209P JC-11992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID547206Antibacterial activity against Shiga toxin-producing Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546920Antibacterial activity against Campylobacter sp. assessed as growth inhibition at =>4 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547189Antibacterial activity against Vibrio sp. assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546912Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.016 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546948Antibacterial activity against Shigella sonnei by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547208Antibacterial activity against Escherichia coli by broth microdilution method in presence of sulfamethoxazolee2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547194Antibacterial activity against Campylobacter coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547200Antibacterial activity against enteropathogenic Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546960Antibacterial activity against Yersinia enterocolitica by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546951Antibacterial activity against Shigella flexneri by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546972Antibacterial activity against Aeromonas sobria by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546658Antibacterial activity against Yersinia sp. assessed as growth inhibition at 0.06 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546650Antibacterial activity against Shigella sp. assessed as growth inhibition at 0.03 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546939Antibacterial activity against Salmonella enterica serovar Newport by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546631Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.03 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546655Antibacterial activity against Yersinia sp. assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547185Antibacterial activity against Vibrio vulnificus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547196Antibacterial activity against Campylobacter coli assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID163961In vitro antibacterial activity against Pseudomonas aeruginosa E-21992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID546957Antibacterial activity against Shigella dysenteriae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547178Antibacterial activity against Vibrio parahaemolyticus assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546969Antibacterial activity against Aeromonas caviae by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546915Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.12 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547199Antibacterial activity against enterotoxigenic Escherichia coli assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546923Antibacterial activity against Escherichia coli assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546956Antibacterial activity against Shigella boydii assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546671Antibacterial activity against Aeromonas sp. assessed as growth inhibition at =>4 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546662Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546930Antibacterial activity against Salmonella enterica serovar Typhi by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID94363In vitro antibacterial activity against Klebsiella pneumoniae K-19661992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
AID547190Antibacterial activity against Vibrio sp. assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547191Antibacterial activity against Campylobacter jejuni by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547177Antibacterial activity against Vibrio parahaemolyticus assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547204Antibacterial activity against enteroaggregative Escherichia coli assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547170Antibacterial activity against Plesiomonas shigelloides by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547197Antibacterial activity against enterotoxigenic Escherichia coli by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546914Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.06 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546647Antibacterial activity against Shigella sp. assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546968Antibacterial activity against Aeromonas hydrophila assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546637Antibacterial activity against Escherichia coli assessed as growth inhibition at 2 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547188Antibacterial activity against Vibrio sp. by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546964Antibacterial activity against Yersinia pseudotuberculosis assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546973Antibacterial activity against Aeromonas sobria assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546639Antibacterial activity against Salmonella sp. assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546924Antibacterial activity against Salmonella enterica serovar Typhimurium by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546679Antibacterial activity against Vibrio sp. assessed as growth inhibition at 0.03 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546672Antibacterial activity against Plesiomonas shigelloides assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547179Antibacterial activity against Vibrio alginolyticus by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547205Antibacterial activity against enteroaggregative Escherichia coli assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546638Antibacterial activity against Escherichia coli assessed as growth inhibition at =>4 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546660Antibacterial activity against Aeromonas sp. assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547184Antibacterial activity against Vibrio fluvialis assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546649Antibacterial activity against Shigella sp. assessed as growth inhibition at 0.016 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546962Antibacterial activity against Yersinia enterocolitica assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546965Antibacterial activity against Yersinia pseudotuberculosis assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546648Antibacterial activity against Shigella sp. assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546627Antibacterial activity against Escherichia coli assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547211Antibacterial activity against blood-borne Escherichia coli assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546654Antibacterial activity against Yersinia sp. assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546961Antibacterial activity against Yersinia enterocolitica assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546632Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.06 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547181Antibacterial activity against Vibrio alginolyticus assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546934Antibacterial activity against Salmonella enterica serovar Paratyphi assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546917Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.5 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546682Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547193Antibacterial activity against Campylobacter jejuni assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546675Antibacterial activity against Vibrio sp. assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546967Antibacterial activity against Aeromonas hydrophila assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547207Antibacterial activity against Shiga toxin-producing Escherichia coli assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546959Antibacterial activity against Shigella dysenteriae assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547210Antibacterial activity against blood-borne Escherichia coli assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546947Antibacterial activity against Salmonella enterica serovar Heidelberg assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546940Antibacterial activity against Salmonella enterica serovar Newport assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547198Antibacterial activity against enterotoxigenic Escherichia coli assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546976Antibacterial activity against Aeromonas veronii assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546932Antibacterial activity against Salmonella enterica serovar Typhi assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546677Antibacterial activity against Vibrio sp. assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546645Antibacterial activity against Salmonella sp. assessed as growth inhibition at 0.12 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546944Antibacterial activity against Salmonella enterica serovar Virchow assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546653Antibacterial activity against Yersinia sp. assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547202Antibacterial activity against enteropathogenic Escherichia coli assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546651Antibacterial activity against Shigella sp. assessed as growth inhibition at 0.06 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547187Antibacterial activity against Vibrio vulnificus assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID608512Antibacterial activity against tolC knockout Escherichia coli KD13972011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
AID546635Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.5 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546644Antibacterial activity against Salmonella sp. assessed as growth inhibition at 0.06 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546666Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.12 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546953Antibacterial activity against Shigella flexneri assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546955Antibacterial activity against Shigella boydii assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546663Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.016 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546659Antibacterial activity against Yersinia sp. assessed as growth inhibition at 0.12 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546678Antibacterial activity against Vibrio sp. assessed as growth inhibition at 0.016 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546918Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 1 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546950Antibacterial activity against Shigella sonnei assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546668Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.5 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547172Antibacterial activity against Plesiomonas shigelloides assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546681Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.004 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546943Antibacterial activity against Salmonella enterica serovar Virchow assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546667Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.25 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546949Antibacterial activity against Shigella sonnei assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546913Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.03 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546657Antibacterial activity against Yersinia sp. assessed as growth inhibition at 0.03 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546919Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 2 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547195Antibacterial activity against Campylobacter coli assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546916Antibacterial activity against Campylobacter sp. assessed as growth inhibition at 0.25 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546641Antibacterial activity against Salmonella sp. assessed as growth inhibition at 0.008 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546974Antibacterial activity against Aeromonas sobria assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547174Antibacterial activity against Vibrio cholerae assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546926Antibacterial activity against Salmonella enterica serovar Typhimurium assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546680Antibacterial activity against Campylobacter sp. assessed as growth inhibition at =<0.002 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546665Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.06 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546946Antibacterial activity against Salmonella enterica serovar Heidelberg assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547183Antibacterial activity against Vibrio fluvialis assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547171Antibacterial activity against Plesiomonas shigelloides assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546929Antibacterial activity against Salmonella enterica serovar Enteritidis assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546636Antibacterial activity against Escherichia coli assessed as growth inhibition at 1 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID547169Antibacterial activity against Aeromonas veronii assessed as percent resistant isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546664Antibacterial activity against Aeromonas sp. assessed as growth inhibition at 0.03 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID546931Antibacterial activity against Salmonella enterica serovar Typhi assessed as percent susceptible isolates by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
AID608513Antibacterial activity against Mycobacterium smegmatis KD11632011Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
AID546633Antibacterial activity against Escherichia coli assessed as growth inhibition at 0.12 ug/ml by broth microdilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (30.61)18.2507
2000's17 (34.69)29.6817
2010's11 (22.45)24.3611
2020's6 (12.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.09 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (6.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (94.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		1.9910halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.0410isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		5.34131aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
enoxacin
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.		2.38201,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
fenbufen
fenbufen: structure; RN given refers to parent cpd		7.13104-oxo monocarboxylic acid;
biphenyls		non-steroidal anti-inflammatory drug
fleroxacin
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.		2.0110difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines		antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
nalidixic acid
[no description available]		2.05101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.0310fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
ofloxacin
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.		3.951303-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		7.730N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tosufloxacin
tosufloxacin: quinolone anti-infective agent; structure given in first source. tosufloxacin : A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin.. 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively.		2.4201,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound
trimethoprim
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.		2.0510aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		6.55262monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.0510beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
penicillanic acid
Penicillanic Acid: A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed). penicillanic acid : A penam that consists of 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane bearing a carboxy group at position 2 and having (2S,5R)-configuration.		2.0510penicillanic acids
erythromycin
Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.		2.0510cyclic ketone;
erythromycin
terbium
Terbium: An element of the rare earth family of metals. It has the atomic symbol Tb, atomic number 65, and atomic weight 158.92.		7.0310f-block element atom;
lanthanoid atom
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		3.411penicillin allergen;
penicillin		antibacterial drug
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		7.0510penicillin allergen;
penicillin		antibacterial drug
sparfloxacin
[no description available]		1.9810fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
prulifloxacin
prulifloxacin: structure given in first source		6.8233fluoroquinolone antibiotic;
quinolone antibiotic
danofloxacin
[no description available]		2.1310quinolines
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		3.4709-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.0610aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
fosfomycin
Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.		2.0210epoxide;
phosphonic acids		antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
clavulanic acid
Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.		3.411oxapenamantibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor
rifaximin
[no description available]		2.0510acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative		antimicrobial agent;
gastrointestinal drug;
orphan drug
piperacillin, tazobactam drug combination
Piperacillin, Tazobactam Drug Combination: An antibiotic combination product of piperacillin and tazobactam, a penicillanic acid derivative with enhanced beta-lactamase inhibitory activity, that is used for the intravenous treatment of intra-abdominal, pelvic, and skin infections and for community-acquired pneumonia of moderate severity. It is also used for the treatment of PSEUDOMONAS AERUGINOSA INFECTIONS.		2.0510
biphenylylacetic acid
biphenylylacetic acid: metabolite of BHD 7538; RN given refers to cpd with unspecified locants for acetic acid moities		2.1310
ConditionIndicatedRelationship StrengthStudiesTrials
E coli Infections
[description not available]		01.9810
Infections, Pseudomonas
[description not available]		01.9810
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		01.9810
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		01.9810
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		07.0510
Gastroenteritis
INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.		07.0510
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		03.5611
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		03.5611
Peripheral Arterial Diseases
[description not available]		02.1310
Peripheral Arterial Disease
Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.		07.1310
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.7330
Infections, Pneumococcal
[description not available]		02.0610
Pneumococcal Infections
Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.		02.0610
Dermatitis, Contact, Phototoxic
[description not available]		02.0710
Polyarthritis
[description not available]		02.0710
Arthritis
Acute or chronic inflammation of JOINTS.		02.0710
Chronic Bronchitis
[description not available]		03.411
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		03.7821
Bronchitis, Chronic
A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.		03.411
Cancer of Lung
[description not available]		03.4111
Lung Neoplasms
Tumors or cancer of the LUNG.		03.4111
Ureteral Calculi
Stones in the URETER that are formed in the KIDNEY. They are rarely more than 5 mm in diameter for larger renal stones cannot enter ureters. They are often lodged at the ureteral narrowing and can cause excruciating renal colic.		02.0410
Acute Kidney Tubular Necrosis
[description not available]		02.6830
Kidney Tubular Necrosis, Acute
Acute kidney failure resulting from destruction of EPITHELIAL CELLS of the KIDNEY TUBULES. It is commonly attributed to exposure to toxic agents or renal ISCHEMIA following severe TRAUMA.		02.6830
Anaphylactic Reaction
[description not available]		01.9910
Anaphylaxis
An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death.		01.9910
Abnormalities, Autosome
[description not available]		01.9910
Weight Gain
Increase in BODY WEIGHT over existing weight.		01.9910
Dyskinesia, Medication-Induced
[description not available]		01.9910
Dyskinesia, Drug-Induced
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)		01.9910
Blood Poisoning
[description not available]		0210
Infections, Respiratory
[description not available]		02.3920
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		02.3920
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		0210
Group A Strep Infection
[description not available]		01.9710
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		01.9710